Related Experiment Video
Updated: May 31, 2025

Manual Therapy for a Chronic Non-Specific Low Back Pain Rat Model
Published on: August 11, 2023
[Muscle relaxants: uncertain risk-benefit balance in chronic pain syndromes.]
Peter K Kurotschka1, David Slawson2, Alice Serafini3
1Department of General practice, University Hospital Würzburg, Germany.
No abstract available in PubMed .
More Related Videos
06:28Biomechanical Changes Related to Low Back Pain: An Innovative Tool for Movement Pattern Assessment and Treatment Evaluation in Rehabilitation
Published on: December 13, 2024
08:33Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Related Concept Videos
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...